CALL FOR PAPERS

Cancer nanomedicine has developed as a consequence of the developments in nanotechnology in the last twenty years; it aims to maximize the efficacy of chemotherapy treatments (effects on pharmacokinetics) and evade the mechanisms of resistance (effects on pharmacodynamics). The ability of cancer to resist conventional means of therapy and high incidence of intolerable side effects by conventional cancer therapeutics is the major reasons for poor therapeutic outcome in cancer. Availing the unique preferential biodistribution of size-controlled nanoparticles in cancer tissues offered means to increase the efficacy and reduce toxicity of therapeutic payloads. It also offers means for the advancement of new cancer treatments from bench to bedside. The aim of this special issue is to highlight current advancement of nanotechnology research in cancer imaging and therapy, with specific attention paid to nanosurface/core functionalization techniques, targeting, codelivery of drugs, and use of imaging agents. Review papers and research articles will be considered for publication.

Potential topics include, but are not limited to:

- ▶ Development of nanotheranostics for personalized therapy in cancer
- ▶ Nanoparticle delivery of macromolecules to cancer cells
- ▶ Nanotechnology means to overcome multidrug resistance
- ▶ QbD approaches in the preparation of cancer theranostic nanoparticles
- ▶ Nanotechnology-based cancer immunotherapy and cancer vaccines
- ▶ Toxicity of the theranostic nanostructures/nanomaterials
- ▶ Multifunctional nanoparticles cancer imaging/therapy
- ▶ Gap in current theranostic approaches

Authors can submit their manuscripts via the Manuscript Tracking System at http://mts.hindawi.com/submit/journals/jnt/nbdct/.

Lead Guest Editor
Aws Alshamsan, King Saud University, Riyadh, Saudi Arabia
aalshamsan@ksu.edu.sa

Guest Editors
Muhammad D. Hussain, California Health Sciences University, Clovis, USA
dhussain@chsu.org

Afsaneh Lavasanifar, University of Alberta, Edmonton, Canada
afsaneh@ualberta.ca

Nicola Tirelli, University of Manchester, Manchester, UK
nicola.tirelli@manchester.ac.uk